Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (12846)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Jul 7, 2017 (publication date) through Nov 22, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Ponziani FR, Zocco MA, D’Aversa F, Pompili M, Gasbarrini A. Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation. World J Gastroenterol 2017; 23(25): 4491-4499 [PMID: 28740337 DOI: 10.3748/wjg.v23.i25.4491] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v23/i25/4491.htm |
| Number | Citing Articles |
| 1 |
Francesca Romana Ponziani, Gaetano Coppola, Pierluigi Rio, Mario Caldarelli, Raffaele Borriello, Giovanni Gambassi, Antonio Gasbarrini, Rossella Cianci. Factors Influencing Microbiota in Modulating Vaccine Immune Response: A Long Way to Go. Vaccines 2023; 11(10): 1609 doi: 10.3390/vaccines11101609
|
| 2 |
Herbert L. DuPont, Graeme N. Forrest. The potential for development of clinically relevant microbial resistance to rifaximin-α: a narrative review. Clinical Microbiology Reviews 2023; 36(4) doi: 10.1128/cmr.00039-23
|
| 3 |
Hidenori OHKUBO, Takaomi KESSOKU, Kosuke TANAKA, Kota TAKAHASHI, Tomohiro TAKATSU, Tsutomu YOSHIHARA, Noboru MISAWA, Keiichi ASHIKARI, Akiko FUYUKI, Shingo KATO, Takuma HIGURASHI, Kunihiro HOSONO, Masato YONEDA, Toshihiro MISUMI, Satoru SHINODA, Vincenzo STANGHELLINI, Atsushi NAKAJIMA. Efficacy and safety of rifaximin in patients with chronic intestinal pseudo-obstruction: a randomized, double-blind, placebo-controlled, phase II—a exploratory trial. Bioscience of Microbiota, Food and Health 2024; 43(2): 135 doi: 10.12938/bmfh.2023-080
|
| 4 |
Jonel Trebicka, Jane Macnaughtan, Bernd Schnabl, Debbie L. Shawcross, Jasmohan S. Bajaj. The microbiota in cirrhosis and its role in hepatic decompensation. Journal of Hepatology 2021; 75: S67 doi: 10.1016/j.jhep.2020.11.013
|
| 5 |
Marina Fortea, Mercé Albert-Bayo, Mar Abril-Gil, John-Peter Ganda Mall, Xavier Serra-Ruiz, Alejandro Henao-Paez, Elba Expósito, Ana María González-Castro, Danila Guagnozzi, Beatriz Lobo, Carmen Alonso-Cotoner, Javier Santos. Present and Future Therapeutic Approaches to Barrier Dysfunction. Frontiers in Nutrition 2021; 8 doi: 10.3389/fnut.2021.718093
|
| 6 |
Rooshi Nathwani, Benjamin Mullish, David Kockerling, Alexander Cole, Nowlan Selvapatt, Ameet Dhar. Review of Rifaximin: A Summary of the Current Evidence and Benefits Beyond Licensed Use. European Medical Journal 2021; : 94 doi: 10.33590/emj/21-00026
|
| 7 |
Marta Maestri, Francesco Santopaolo, Maurizio Pompili, Antonio Gasbarrini, Francesca Romana Ponziani. Gut microbiota modulation in patients with non-alcoholic fatty liver disease: Effects of current treatments and future strategies. Frontiers in Nutrition 2023; 10 doi: 10.3389/fnut.2023.1110536
|
| 8 |
Ayodeji Awoyemi, Cristiane Mayerhofer, Alex S. Felix, Johannes R. Hov, Samuel D. Moscavitch, Knut Tore Lappegård, Anders Hovland, Sigrun Halvorsen, Bente Halvorsen, Ida Gregersen, Asbjørn Svardal, Rolf K. Berge, Simen H. Hansen, Alexandra Götz, Kristian Holm, Pål Aukrust, Sissel Åkra, Ingebjørg Seljeflot, Svein Solheim, Andrea Lorenzo, Lars Gullestad, Marius Trøseid, Kaspar Broch. Rifaximin or Saccharomyces boulardii in heart failure with reduced ejection fraction: Results from the randomized GutHeart trial. EBioMedicine 2021; 70: 103511 doi: 10.1016/j.ebiom.2021.103511
|
| 9 |
Vladimir Ivashkin, Oleg Shifrin, Roman Maslennikov, Elena Poluektova, Alexander Korolev, Anna Kudryavtseva, George Krasnov, Nona Benuni, Giovanni Barbara. Eubiotic effect of rifaximin is associated with decreasing abdominal pain in symptomatic uncomplicated diverticular disease: results from an observational cohort study. BMC Gastroenterology 2023; 23(1) doi: 10.1186/s12876-023-02690-x
|
| 10 |
Xiaojun Zhuang, Zhenyi Tian, Mei Luo, Lishou Xiong. Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome. BMC Gastroenterology 2020; 20(1) doi: 10.1186/s12876-020-01336-6
|
| 11 |
Nahum Mendez-Sanchez, Carlos Esteban Coronel-Castillo, Jacqueline Cordova-Gallardo, Xingshun Qi. Antibiotics in Chronic Liver Disease and Their Effects on Gut Microbiota. Antibiotics 2023; 12(10): 1475 doi: 10.3390/antibiotics12101475
|
| 12 |
M. Fidelle, L. Derosa, B. Routy, L. Zitvogel. Contourner la résistance à l’immunothérapie des cancers : interventions centrées sur le microbiome intestinal. Bulletin de l'Académie Nationale de Médecine 2021; 205(4): 364 doi: 10.1016/j.banm.2021.01.022
|
| 13 |
Francesco Santopaolo, Gaetano Coppola, Lucia Giuli, Antonio Gasbarrini, Francesca Romana Ponziani. Influence of Gut–Liver Axis on Portal Hypertension in Advanced Chronic Liver Disease: The Gut Microbiome as a New Protagonist in Therapeutic Management. Microbiology Research 2022; 13(3): 539 doi: 10.3390/microbiolres13030038
|
| 14 |
Lucia Redondo-Cuevas, Lucia Belloch, Vanesa Martín-Carbonell, Angela Nicolás, Iulia Alexandra, Laura Sanchis, Marina Ynfante, Michel Colmenares, María Mora, Ana Reyes Liebana, Beatriz Antequera, Francisco Grau, José Ramón Molés, Rubén Cuesta, Samuel Díaz, Noelia Sancho, Héctor Tomás, José Gonzalvo, Mercedes Jaén, Eva Sánchez, Ana Garayoa, Nadia Moreno, Ana Gallén, Ernesto Cortés-Castell, Xavier Cortés-Rizo. Do Herbal Supplements and Probiotics Complement Antibiotics and Diet in the Management of SIBO? A Randomized Clinical Trial. Nutrients 2024; 16(7): 1083 doi: 10.3390/nu16071083
|
| 15 |
Vasile Valeriu Lupu, Anca Adam Raileanu, Cristina Maria Mihai, Ionela Daniela Morariu, Ancuta Lupu, Iuliana Magdalena Starcea, Otilia Elena Frasinariu, Adriana Mocanu, Felicia Dragan, Silvia Fotea. The Implication of the Gut Microbiome in Heart Failure. Cells 2023; 12(8): 1158 doi: 10.3390/cells12081158
|
| 16 |
E. V. Golovanova. Cyclic rifaximin and soluble dietary fiber therapy for symptomatic diverticular disease: effective prevention of complications. Medical Council 2019; (3): 98 doi: 10.21518/2079-701X-2019-3-98-107
|
| 17 |
Tilman Sauerbruch, Martin Hennenberg, Jonel Trebicka, Ulrich Beuers. Bile Acids, Liver Cirrhosis, and Extrahepatic Vascular Dysfunction. Frontiers in Physiology 2021; 12 doi: 10.3389/fphys.2021.718783
|
| 18 |
Puru Rattan, Carlos D. Minacapelli, Vinod Rustgi. The Microbiome and Hepatocellular Carcinoma. Liver Transplantation 2020; 26(10): 1316 doi: 10.1002/lt.25828
|
| 19 |
Connor Stewart, Tim Jang, George Mo, Nader Mohamed, Maria Poplawska, Ogechukwu Egini, Dibyendu Dutta, Seah H. Lim. Antibiotics to modify sickle cell disease vaso-occlusive crisis?. Blood Reviews 2021; 50: 100867 doi: 10.1016/j.blre.2021.100867
|
| 20 |
Shiv K. Sarin, Apurva Pande, Bernd Schnabl. Microbiome as a therapeutic target in alcohol-related liver disease. Journal of Hepatology 2019; 70(2): 260 doi: 10.1016/j.jhep.2018.10.019
|
| 21 |
Georgia Brown, Emily C. Hoedt, Simon Keely, Ayesha Shah, Marjorie M. Walker, Gerald Holtmann, Nicholas J. Talley. Role of the duodenal microbiota in functional dyspepsia. Neurogastroenterology & Motility 2022; 34(11) doi: 10.1111/nmo.14372
|
| 22 |
Mi-Young Kim, Sang-Woon Choi. Dietary modulation of gut microbiota for the relief of irritable bowel syndrome. Nutrition Research and Practice 2021; 15(4): 411 doi: 10.4162/nrp.2021.15.4.411
|
| 23 |
O. M. Drapkina, L. B. Lazebnik, I. G. Bakulin, E. V. Skazyvaeva, N. V. Bakulina, S. I. Sitkin, M. I. Skalinskaya, M. S. Zhuravleva, E. B. Avalueva, M. A. Livzan, D. S. Bordin, A. I. Khavkin. Colonic diverticular disease: clinical presentation, diagnosis, treatment, and prevention Clinical guidelines of the Russian Scientific Medical Society of Internal Medicine, the Gastroenterological Scientific Society of Russia, and the North- West Society of Gastroenterologists and Hepatologists. Experimental and Clinical Gastroenterology 2023; (2): 33 doi: 10.31146/1682-8658-ecg-210-2-33-69
|
| 24 |
Sharlize Pedroza Matute, Sasitaran Iyavoo. Exploring the gut microbiota: lifestyle choices, disease associations, and personal genomics. Frontiers in Nutrition 2023; 10 doi: 10.3389/fnut.2023.1225120
|
| 25 |
Aylin Deljavan Ghodrati, Tansel Comoglu. Rifaximin and alternative agents in the management of irritable bowel syndrome: A comprehensive review. Archiv der Pharmazie 2024; 357(10) doi: 10.1002/ardp.202400356
|
| 26 |
Joshua Henrina, Irvan Cahyadi, Hoo Felicia Hadi Gunawan, Leonardo Paskah Suciadi. Gut Microbiota as a Potential Treatment Target in Patient with Chronic Heart Failure. SN Comprehensive Clinical Medicine 2020; 2(9): 1614 doi: 10.1007/s42399-020-00436-4
|
| 27 |
Takaomi Kessoku, Takashi Kobayashi, Kento Imajo, Kosuke Tanaka, Atsushi Yamamoto, Kota Takahashi, Yuki Kasai, Anna Ozaki, Michihiro Iwaki, Asako Nogami, Yasushi Honda, Yuji Ogawa, Shingo Kato, Takuma Higurashi, Kunihiro Hosono, Masato Yoneda, Takayuki Okamoto, Haruki Usuda, Koichiro Wada, Noritoshi Kobayashi, Satoru Saito, Atsushi Nakajima. Endotoxins and Non-Alcoholic Fatty Liver Disease. Frontiers in Endocrinology 2021; 12 doi: 10.3389/fendo.2021.770986
|
| 28 |
Daniela Campion, Ilaria Giovo, Paola Ponzo, Giorgio M Saracco, Federico Balzola, Carlo Alessandria. Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis. World Journal of Hepatology 2019; 11(6): 489-512 doi: 10.4254/wjh.v11.i6.489
|
| 29 |
Oleg V. Golovenko, Alexey O. Golovenko. Opinions of gastroenterologists about intestinal microbiota modulating agents: results of the survey in focus groups. Consilium Medicum 2023; 25(5): 344 doi: 10.26442/20751753.2023.5.202250
|
| 30 |
Beatriz Sanchez-Jimenez, Norberto C Chavez-Tapia, Janus C Jakobsen, Dimitrinka Nikolova, Christian Gluud. Antibiotic prophylaxis for people with cirrhosis and variceal bleeding. Cochrane Database of Systematic Reviews 2018; doi: 10.1002/14651858.CD013214
|
| 31 |
Lucia Giuli, Marta Maestri, Francesco Santopaolo, Maurizio Pompili, Francesca Romana Ponziani. Gut Microbiota and Neuroinflammation in Acute Liver Failure and Chronic Liver Disease. Metabolites 2023; 13(6): 772 doi: 10.3390/metabo13060772
|
| 32 |
Qiujin Jia, Hao Li, Huan Zhou, Xiaonan Zhang, Ao Zhang, Yingyu Xie, Yanyang Li, Shichao Lv, Junping Zhang. Role and Effective Therapeutic Target of Gut Microbiota in Heart Failure. Cardiovascular Therapeutics 2019; 2019: 1 doi: 10.1155/2019/5164298
|
| 33 |
Hanzhi Xu, Xun Qiu, Zhoucheng Wang, Kai Wang, Yawen Tan, Fengqiang Gao, Marcos Vinicius Perini, Xiao Xu. Role of the portal system in liver regeneration: From molecular mechanisms to clinical management. Liver Research 2024; 8(1): 1 doi: 10.1016/j.livres.2024.01.002
|
| 34 |
Barbara Skrzydło-Radomańska, Bożena Cukrowska. How to Recognize and Treat Small Intestinal Bacterial Overgrowth?. Journal of Clinical Medicine 2022; 11(20): 6017 doi: 10.3390/jcm11206017
|
| 35 |
Giovanni Marasco, Francesco Buttitta, Cesare Cremon, Maria Raffaella Barbaro, Vincenzo Stanghellini, Giovanni Barbara. The role of microbiota and its modulation in colonic diverticular disease. Neurogastroenterology & Motility 2023; 35(12) doi: 10.1111/nmo.14615
|
| 36 |
Iqra Usman, Aamir Anwar, Shivang Shukla, Priya Pathak. Mechanistic Review on the Role of Gut Microbiota in the Pathology of
Cardiovascular Diseases. Cardiovascular & Hematological Disorders-Drug Targets 2024; 24(1): 13 doi: 10.2174/011871529X310857240607103028
|
| 37 |
Yafei Chen, Zuoyi Jiang, Zhihai Lei, Jihui Ping, Juan Su. Effect of rifaximin on gut-lung axis in mice infected with influenza A virus. Comparative Immunology, Microbiology and Infectious Diseases 2021; 75: 101611 doi: 10.1016/j.cimid.2021.101611
|
| 38 |
Emma Bruder, Olivier Espéli. Escherichia coli bacteria associated with Crohn’s disease persist within phagolysosomes. Current Opinion in Microbiology 2022; 70: 102206 doi: 10.1016/j.mib.2022.102206
|
| 39 |
Svenja Nolte, Karsten Krüger, Claudia Lenz, Karen Zentgraf. Optimizing the Gut Microbiota for Individualized Performance Development in Elite Athletes. Biology 2023; 12(12): 1491 doi: 10.3390/biology12121491
|
| 40 |
Sara Montagnese, Francesco Paolo Russo, Piero Amodio, Patrizia Burra, Antonio Gasbarrini, Carmela Loguercio, Giulio Marchesini, Manuela Merli, Francesca Romana Ponziani, Oliviero Riggio, Carmelo Scarpignato. Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). Digestive and Liver Disease 2019; 51(2): 190 doi: 10.1016/j.dld.2018.11.035
|
| 41 |
Parna Pathak, Arup Choudhury. Journal Summary: Do Antibiotics Predispose to the Development of Inflammatory Bowel Disease?. Journal of Gastrointestinal Infections 2024; 14(01): 017 doi: 10.1055/s-0044-1788549
|
| 42 |
Hui-Ting Chen, Hong-Li Huang, Yong-Qiang Li, Hao-Ming Xu, Yong-Jian Zhou. Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view. World Journal of Gastroenterology 2020; 26(16): 1901-1911 doi: 10.3748/wjg.v26.i16.1901
|
| 43 |
Donglei Sun, Chao Zuo, Wei Huang, Jingjing Wang, Zunzhen Zhang. Triclosan targeting of gut microbiome ameliorates hepatic steatosis in high fat diet-fed mice. The Journal of Antibiotics 2022; 75(6): 341 doi: 10.1038/s41429-022-00522-w
|
| 44 |
Brian Bicknell, Ann Liebert, Thomas Borody, Geoffrey Herkes, Craig McLachlan, Hosen Kiat. Neurodegenerative and Neurodevelopmental Diseases and the Gut-Brain Axis: The Potential of Therapeutic Targeting of the Microbiome. International Journal of Molecular Sciences 2023; 24(11): 9577 doi: 10.3390/ijms24119577
|
| 45 |
Haiming Hu, Aizhen Lin, Mingwang Kong, Xiaowei Yao, Mingzhu Yin, Hui Xia, Jun Ma, Hongtao Liu. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives. Journal of Gastroenterology 2020; 55(2): 142 doi: 10.1007/s00535-019-01649-8
|
| 46 |
Federica Di Vincenzo, Alberto Nicoletti, Marcantonio Negri, Federica Vitale, Lorenzo Zileri Dal Verme, Antonio Gasbarrini, Francesca Romana Ponziani, Lucia Cerrito. Gut Microbiota and Antibiotic Treatments for the Main Non-Oncologic Hepato-Biliary-Pancreatic Disorders. Antibiotics 2023; 12(6): 1068 doi: 10.3390/antibiotics12061068
|
| 47 |
Aleksandra Blonska, Marcin Chojnacki, Anna Macieja, Janusz Blasiak, Ireneusz Majsterek, Jan Chojnacki, Tomasz Poplawski. Tryptophan Metabolism in Postmenopausal Women with Functional Constipation. International Journal of Molecular Sciences 2023; 25(1): 273 doi: 10.3390/ijms25010273
|
| 48 |
O. S. Shifrin, E. A. Poluektova, A. V. Korolev, T. I. Semenova, M. V. Shein, G. N. Leksikova, O. A. Tokareva, O. E. Davydova, P. S. Andreev, S. E. Katorkin, A. A. Chernov, A. V. Zhuravlev, O. S. Sek, A. A. Kopina, N. Yu. Samokhina, Yu. V. Gorozhankina, M. F. Samigullin, V. S. Groshilin, E. N. Borisova, T. A. Petrova, I. Yu. Pirogova, S. V. Mednikov, N. V. Smagin, A. S. Sarsenbaeva, N. V. Smirnova, L. G. Kirsanova, N. M. Malyutina, M. A. Smirnova, E. N. Shleikova, V. T. Ivashkin. Russian Non-Interventional Study of the Efficacy and Tolerability of Rifaximin-α Therapy in Patients with Uncomplicated Diverticular Disease under the Conditions of Outpatient Practice. Russian Journal of Gastroenterology, Hepatology, Coloproctology 2020; 30(1): 14 doi: 10.22416/1382-4376-2020-30-1-14-25
|
| 49 |
E. Yu. Plotnikova. Rifaximin: unique selective antibiotic for the treatment of gastrointestinal diseases. Meditsinskiy sovet = Medical Council 2021; (5): 167 doi: 10.21518/2079-701X-2021-5-167-174
|
| 50 |
Danica Bajic, Adrian Niemann, Anna-Katharina Hillmer, Raquel Mejias-Luque, Sena Bluemel, Melissa Docampo, Maja C Funk, Elena Tonin, Michael Boutros, Bernd Schnabl, Dirk H Busch, Tsuyoshi Miki, Roland M Schmid, Marcel R M van den Brink, Markus Gerhard, Christoph K Stein-Thoeringer. Gut Microbiota-Derived Propionate Regulates the Expression of Reg3 Mucosal Lectins and Ameliorates Experimental Colitis in Mice. Journal of Crohn's and Colitis 2020; 14(10): 1462 doi: 10.1093/ecco-jcc/jjaa065
|
| 51 |
Aleksandra Bołdys, Łukasz Bułdak, Mateusz Maligłówka, Stanisław Surma, Bogusław Okopień. Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease. Medicina 2023; 59(10): 1789 doi: 10.3390/medicina59101789
|
| 52 |
Carmelo Scarpignato, Neil Stollman. Colonic Diverticular Disease. 2022; : 209 doi: 10.1007/978-3-030-93761-4_18
|
| 53 |
Elina Manzhalii, Valentyna Moyseyenko, Vitalii Kondratiuk, Nataliia Molochek, Tetyana Falalyeyeva, Nazarii Kobyliak. Effect of a specific <i>Escherichia coli Nissle 1917</i> strain on minimal/mild hepatic encephalopathy treatment. World Journal of Hepatology 2022; 14(3): 634-646 doi: 10.4254/wjh.v14.i3.634
|
| 54 |
Domenico Ferro, Francesco Baratta, Daniele Pastori, Nicholas Cocomello, Alessandra Colantoni, Francesco Angelico, Maria Del Ben. New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress. Nutrients 2020; 12(9): 2762 doi: 10.3390/nu12092762
|
| 55 |
Ștefan-Sorin Aramă. Irritable bowel syndrome and probiotics place in therapeutic strategies. Infectio.ro 2018; (1): 9 doi: 10.26416/Inf.56.4.2018.2188
|
| 56 |
Daniele Zama, Gianluca Bossù, Davide Leardini, Edoardo Muratore, Elena Biagi, Arcangelo Prete, Andrea Pession, Riccardo Masetti. Insights into the role of intestinal microbiota in hematopoietic stem-cell transplantation. Therapeutic Advances in Hematology 2020; 11 doi: 10.1177/2040620719896961
|
| 57 |
Cristina Tocia, Irina Magdalena Dumitru, Luana Alexandrescu, Lucian Cristian Petcu, Eugen Dumitru. Does rifaximin offer any promise in Crohn's disease in remission and concurrent irritable bowel syndrome-like symptoms?. Medicine 2021; 100(1): e24059 doi: 10.1097/MD.0000000000024059
|
| 58 |
Jifeng Yu, Hao Sun, Weijie Cao, Lijie Han, Yongping Song, Dingming Wan, Zhongxing Jiang. Applications of gut microbiota in patients with hematopoietic stem-cell transplantation. Experimental Hematology & Oncology 2020; 9(1) doi: 10.1186/s40164-020-00194-y
|
| 59 |
Vikram Mahajan, Suman Singh, Priyanka Thakur, Amisha Kukreja, Rohit Negi. Severe Sunburn-Like Adverse Cutaneous Drug Reaction in a Patient on Treatment with
Rifaximin: A Rare Case of Acute Phototoxic Drug Reaction. EMJ Dermatology 2022; doi: 10.33590/emjdermatol/21-00233
|
| 60 |
Shan Jiang, Xiaolu Wei, Hongjie Wang, Yanyan Zhou, Lihua Chen, Lianmei Wang, Feng Wang, Qilong Wu, Nan Si, Baolin Bian, Haiyu Zhao. Biotransformed bear bile powder alleviates diet-induced nonalcoholic fatty liver disease in mice by regulating the gut microbiota and reversing lipid metabolism. Arabian Journal of Chemistry 2024; 17(2): 105578 doi: 10.1016/j.arabjc.2023.105578
|
| 61 |
Fulvio Pandico, Anna Citarella, Simona Cammarota, Francesca Futura Bernardi, Ernesto Claar, Carmine Coppola, Marianna Cozzolino, Federica De Rosa, Massimo Di Gennaro, Marianna Fogliasecca, Roberta Giordana, Daniela Pacella, Alessandro Russo, Vito Salerno, Luca Scafa, Ugo Trama. Rifaximin Use, Adherence and Persistence in Patients with Hepatic Encephalopathy: A Real-World Study in the South of Italy. Journal of Clinical Medicine 2023; 12(13): 4515 doi: 10.3390/jcm12134515
|
| 62 |
Xin-Yue Lv, Hui-Guo Ding, Jun-Fu Zheng, Chun-Lei Fan, Lei Li. Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world study. World Journal of Gastroenterology 2020; 26(2): 199-218 doi: 10.3748/wjg.v26.i2.199
|
| 63 |
Aikaterini Mastoraki, Dimitrios Schizas, Athina Tousia, George Chatzopoulos, Anastasia Gkiala, Athanasios Syllaios, Maximos Frountzas, Pantelis Vassiliu, Georgios E. Theodoropoulos, Evangelos Felekouras. Evaluation of molecular and genetic predisposing parameters at diverticular disease of the colon. International Journal of Colorectal Disease 2021; 36(5): 903 doi: 10.1007/s00384-020-03812-7
|
| 64 |
Phillipp Hartmann, Bernd Schnabl. New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease. Seminars in Liver Disease 2021; 41(01): 087 doi: 10.1055/s-0040-1719174
|
| 65 |
S. Ghanem, C.J. Kim, D. Dutta, M. Salifu, S.H. Lim. Antimicrobial therapy during cancer treatment: Beyond antibacterial effects. Journal of Internal Medicine 2021; 290(1): 40 doi: 10.1111/joim.13238
|
| 66 |
Buyun Qian, Kaiyu Zhang, Yuan Li, Kangyun Sun. Update on gut microbiota in cardiovascular diseases. Frontiers in Cellular and Infection Microbiology 2022; 12 doi: 10.3389/fcimb.2022.1059349
|
| 67 |
E. A. Kashukh, E. A. Poluektova, A. V. Kudryavtseva, G. S. Krasnov, V. I. Kazey, P. D. Sobolev, P. V. Gremyakova, V. T. Ivashkin. Effect of Rifaximin and a Multi-Strain Probiotic on the Intestinal Microbiome and Cardiovascular Risk Indicators in Patients with Coronary Heart Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology 2019; 29(4): 38 doi: 10.22416/1382-4376-2019-29-4-38-49
|
| 68 |
Aravind Thavamani, Senthilkumar Sankararaman, Hilmi Al-Shakhshir, Mauricio Retuerto, Sujithra Velayuthan, Thomas J. Sferra, Mahmoud Ghannoum. Impact of Erythromycin as a Prokinetic on the Gut Microbiome in Children with Feeding Intolerance—A Pilot Study. Antibiotics 2023; 12(11): 1606 doi: 10.3390/antibiotics12111606
|
| 69 |
Camila Fontoura Acosta Ribeiro, Gislaine Greice de Oliveira Silva Silveira, Elizabete de Souza Cândido, Marlon Henrique Cardoso, Cristiano Marcelo Espínola Carvalho, Octávio Luiz Franco. Effects of Antibiotic Treatment on Gut Microbiota and How to Overcome Its Negative Impacts on Human Health. ACS Infectious Diseases 2020; 6(10): 2544 doi: 10.1021/acsinfecdis.0c00036
|
| 70 |
Mateusz Sobczyk, Mikołaj Porzak, Daria Żuraw, Alicja Sodolska, Paulina Oleksa, Kacper Jasiński. Small intestinal bacterial overgrowth – current, novel and possible future methods of treatment and diagnosis. Prospects in Pharmaceutical Sciences 2024; 22(2): 65 doi: 10.56782/pps.196
|
| 71 |
Cyriac Abby Philips, Philip Augustine, Karthik Ganesan, Shatakshi Ranade, Varun Chopra, Kunal Patil, Sonie Shende, Rizwan Ahamed, Sandeep Kumbar, Sasidharan Rajesh, Tom George, Meera Mohanan, Narain Mohan, Nikhil Phadke, Mridula Rani, Arjun Narayanan, Suchetha M. Jagan. The role of gut microbiota in clinical complications, disease severity, and treatment response in severe alcoholic hepatitis. Indian Journal of Gastroenterology 2022; 41(1): 37 doi: 10.1007/s12664-021-01157-9
|
| 72 |
Sabine Becker, Louise B. Grode, Ole K. Bonderup. Rifaximin Treatment of Collagenous Colitis: A Randomised, Double-Blind, Placebo-Controlled Trial. Inflammatory Intestinal Diseases 2024; 9(1): 22 doi: 10.1159/000536124
|
| 73 |
Maximos Frountzas, Victoria Michalopoulou, Georgia Georgiou, Despoina Kanata, Maria Matiatou, Despina Kimpizi, Georgia Matthaiou, Spilios Spiliotopoulos, Dimitrios Vouros, Konstantinos G. Toutouzas, George E. Theodoropoulos. The Impact of Mechanical Bowel Preparation and Oral Antibiotics in Colorectal Cancer Surgery (MECCA Study): A Prospective Randomized Clinical Trial. Journal of Clinical Medicine 2024; 13(4): 1162 doi: 10.3390/jcm13041162
|
| 74 |
Carlo Airola, Andrea Severino, Serena Porcari, William Fusco, Benjamin H. Mullish, Antonio Gasbarrini, Giovanni Cammarota, Francesca Romana Ponziani, Gianluca Ianiro. Future Modulation of Gut Microbiota: From Eubiotics to FMT, Engineered Bacteria, and Phage Therapy. Antibiotics 2023; 12(5): 868 doi: 10.3390/antibiotics12050868
|
| 75 |
Gauri S Khatri, Christine Kurian, Asha Anand, Paari KA. Gut Homeostasis; Microbial Cross Talks in Health and Disease Management. Current Research in Nutrition and Food Science Journal 2021; 9(3): 1017 doi: 10.12944/CRNFSJ.9.3.28
|
| 76 |
Ishfaq Hassan Mir, Saqib Hassan, Joseph Selvin, Chinnasamy Thirunavukkarasu. Human Microbiome in Health, Disease, and Therapy. 2023; : 127 doi: 10.1007/978-981-99-5114-7_7
|
| 77 |
An‐Tian Chen, Jian Zhang, Yuhui Zhang. Gut microbiota in heart failure and related interventions. iMeta 2023; 2(3) doi: 10.1002/imt2.125
|
| 78 |
Y. A. Sorokina, N. A. Petunina, S. D. Sinyushkina, A. V. Gorinova, M. I. Pryazhnikova, S. A. Sukhanov, A. S. Rudakov, O. V. Zanozina. Cardiovascular pathology and intestinal microbiome relationship: potential targets of pharmacotherapy. Meditsinskiy sovet = Medical Council 2023; 17(9): 137 doi: 10.21518/ms2023-158
|
| 79 |
Sarah Lechner, Matthew Yee, Berkeley N. Limketkai, Edward A. Pham. Fecal Microbiota Transplantation for Chronic Liver Diseases: Current Understanding and Future Direction. Digestive Diseases and Sciences 2020; 65(3): 897 doi: 10.1007/s10620-020-06100-0
|
| 80 |
Jozef Kuzma, Dittmar Chmelař, Michal Hájek, Alexandra Lochmanová, Ivan Čižnár, Miroslav Rozložník, Miloslav Klugar. The role of intestinal microbiota in the pathogenesis of colorectal carcinoma. Folia Microbiologica 2020; 65(1): 17 doi: 10.1007/s12223-019-00706-2
|
| 81 |
Mohamed Tausif Siddiqui, Gail A.M. Cresci. Microbiota reprogramming for treatment of alcohol-related liver disease. Translational Research 2020; 226: 26 doi: 10.1016/j.trsl.2020.07.004
|
| 82 |
Joanna Nycz, Alicja Zajdel. Mikrobiota jelitowa a leki. Interakcje wpływające na skuteczność i bezpieczeństwo farmakoterapii. Postępy Higieny i Medycyny Doświadczalnej 2021; 75(1): 762 doi: 10.2478/ahem-2021-0009
|
| 83 |
Olga K. Didyk, Volodymyr V. Chernyavskyi, Vadym P. Shypulin, Victoriia V. Tishchenko. Effectiveness of rifaximin and probiotics for the correction of intestinal permeability in patients with metabolic-associated fatty liver disease in combination with type 2 diabetes mellitus. Wiadomości Lekarskie 2024; 77(4): 732 doi: 10.36740/WLek202404118
|
| 84 |
Francesco Di Pierro, Marco Pane. Bifidobacterium longum W11: Uniqueness and individual or combined clinical use in association with rifaximin. Clinical Nutrition ESPEN 2021; 42: 15 doi: 10.1016/j.clnesp.2020.12.025
|
| 85 |
Beatriz Sanchez-Jimenez, Norberto C Chavez-Tapia, Janus C Jakobsen, Dimitrinka Nikolova, Christian Gluud. Antibiotic prophylaxis versus placebo or no intervention for people with cirrhosis and variceal bleeding. Cochrane Database of Systematic Reviews 2018; doi: 10.1002/14651858.CD013175
|
| 86 |
Yahkub Babatunde Mutalub, Monsurat Abdulwahab, Alkali Mohammed, Aishat Mutalib Yahkub, Sameer Badri AL-Mhanna, Wardah Yusof, Suk Peng Tang, Aida Hanum Ghulam Rasool, Siti Safiah Mokhtar. Gut Microbiota Modulation as a Novel Therapeutic Strategy in Cardiometabolic Diseases. Foods 2022; 11(17): 2575 doi: 10.3390/foods11172575
|
| 87 |
Brian E. Lacy, Patrick Gagnon-Sanschagrin, Zeev Heimanson, Rebecca Bungay, Remi Bellefleur, Annie Guérin, Brock Bumpass, Danellys Borroto, George Joseph, Ankur A. Dashputre. Treatment-Free Interval: A Novel Approach to Assessing Real-World Treatment Effectiveness and Economic Impact Among Patients with Irritable Bowel Syndrome with Diarrhea. Advances in Therapy 2024; 41(6): 2253 doi: 10.1007/s12325-024-02832-x
|
| 88 |
Lianjun Yang, Bin Liu, Junchi Zheng, Jincheng Huang, Qinghao Zhao, Jinshi Liu, Zhihai Su, Min Wang, Zhifei Cui, Tingxuan Wang, Weicong Zhang, Qingchu Li, Hai Lu. Rifaximin Alters Intestinal Microbiota and Prevents Progression of Ankylosing Spondylitis in Mice. Frontiers in Cellular and Infection Microbiology 2019; 9 doi: 10.3389/fcimb.2019.00044
|
| 89 |
Peng Zhao, Suhong Zhao, Jinwei Tian, Xinxin Liu. Significance of Gut Microbiota and Short-Chain Fatty Acids in Heart Failure. Nutrients 2022; 14(18): 3758 doi: 10.3390/nu14183758
|
| 90 |
Marwa Salih Al-Naimi, Ahmed R. Abu-Raghif, Hayder Adnan Fawzi. Novel therapeutic effects of rifaximin in combination with methylprednisolone for LPS-induced oxidative stress and inflammation in mice: An in vivo study. Toxicology Reports 2024; 13: 101808 doi: 10.1016/j.toxrep.2024.101808
|
| 91 |
Alix Bruneau, Jana Hundertmark, Adrien Guillot, Frank Tacke. Molecular and Cellular Mediators of the Gut-Liver Axis in the Progression of Liver Diseases. Frontiers in Medicine 2021; 8 doi: 10.3389/fmed.2021.725390
|
| 92 |
Audrey V Adler, Hailee R Ciccotti, Spencer J H Trivitt, Roland C J Watson, Mark S Riddle. What’s new in travellers’ diarrhoea: updates on epidemiology, diagnostics, treatment and long-term consequences. Journal of Travel Medicine 2022; 29(1) doi: 10.1093/jtm/taab099
|
| 93 |
Salma Sultan, Mohammed El-Mowafy, Abdelaziz Elgaml, Tamer A. E. Ahmed, Hebatoallah Hassan, Walid Mottawea. Metabolic Influences of Gut Microbiota Dysbiosis on Inflammatory Bowel Disease. Frontiers in Physiology 2021; 12 doi: 10.3389/fphys.2021.715506
|
| 94 |
Jie-Yu Chuang. Stressor-Specific Microbiota Intervention. Frontiers in Nutrition 2022; 9 doi: 10.3389/fnut.2022.870665
|
| 95 |
Nimalan Arjun Jeganathan, Emily R Davenport, Gregory S Yochum, Walter A Koltun. The microbiome of diverticulitis. Current Opinion in Physiology 2021; 22: 100452 doi: 10.1016/j.cophys.2021.06.006
|
| 96 |
Haonan Li, Yujiao Xiang, Zemeng Zhu, Wei Wang, Zhijun Jiang, Mingyue Zhao, Shuyue Cheng, Fang Pan, Dexiang Liu, Roger C. M. Ho, Cyrus S. H. Ho. Rifaximin-mediated gut microbiota regulation modulates the function of microglia and protects against CUMS-induced depression-like behaviors in adolescent rat. Journal of Neuroinflammation 2021; 18(1) doi: 10.1186/s12974-021-02303-y
|
| 97 |
Bálint Baráth, Dávid K. Jász, Tamara Horváth, Bence Baráth, Gergely Maróti, Gerda Strifler, Gabriella Varga, Lilla Sándor, Domonkos Perényi, Szabolcs Tallósy, Tibor Donka, Péter Jávor, Mihály Boros, Petra Hartmann. Mitochondrial Side Effects of Surgical Prophylactic Antibiotics Ceftriaxone and Rifaximin Lead to Bowel Mucosal Damage. International Journal of Molecular Sciences 2022; 23(9): 5064 doi: 10.3390/ijms23095064
|
| 98 |
Hamed Memariani, Mojtaba Memariani. The Role of Gut Microbiota in Psoriasis: Current Knowledge and Emerging Therapeutic Interventions. International Journal of Enteric Pathogens 2024; 12(1): 26 doi: 10.34172/ijep.5636
|
| 99 |
Fengqian Chen, Qi Liu. Demystifying phytoconstituent-derived nanomedicines in their immunoregulatory and therapeutic roles in inflammatory diseases. Advanced Drug Delivery Reviews 2022; 186: 114317 doi: 10.1016/j.addr.2022.114317
|
| 100 |
Kashif Mohd Siddiqui, Sumeet Attri, Massimo Orlando, Filippo Lelli, Valeria Maida, Dominique Damais-Thabut, Soe Thiha Maung. Cost-Effectiveness of Rifaximin-α versus Lactulose for the Treatment of Recurrent Episodes of Overt Hepatic Encephalopathy: A Meta-Analysis. GastroHep 2022; 2022: 1 doi: 10.1155/2022/1298703
|
| 101 |
Anna Pietrzak, Grażyna Rydzewska, Katarzyna Neubauer, Tomasz Banasiewicz, Wiesław Tarnowski. One-year cyclic therapy with rifaximin-α is effective in the treatment of SUDD (Symptomatic Uncomplicated Diverticular Disease) also in patients with a history of complicated diverticulitis. Polish Journal of Surgery 2023; 95(4): 54 doi: 10.5604/01.3001.0053.8079
|
| 102 |
Hasnain N. Methiwala, Bhupesh Vaidya, Vamsi Krishna Addanki, Mahendra Bishnoi, Shyam Sunder Sharma, Kanthi Kiran Kondepudi. Gut microbiota in mental health and depression: role of pre/pro/synbiotics in their modulation. Food & Function 2021; 12(10): 4284 doi: 10.1039/D0FO02855J
|
| 103 |
Muhammad Faraz Raghib, Evanthia Bernitsas. From Animal Models to Clinical Trials: The Potential of Antimicrobials in Multiple Sclerosis Treatment. Biomedicines 2023; 11(11): 3069 doi: 10.3390/biomedicines11113069
|
| 104 |
Francesca Romana Ponziani, Alberto Nicoletti, Antonio Gasbarrini, Maurizio Pompili. Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma. Therapeutic Advances in Medical Oncology 2019; 11 doi: 10.1177/1758835919848184
|
| 105 |
Xi-Chen Zhao, Xiao-Yun Sun, Bo Ju, Fan-Jun Meng, Hong-Guo Zhao. Acquired aplastic anemia: Is bystander insult to autologous hematopoiesis driven by immune surveillance against malignant cells?. World Journal of Stem Cells 2020; 12(11): 1429-1438 doi: 10.4252/wjsc.v12.i11.1429
|
| 106 |
Iain O’Neill. A Worldwide Perspective on Diagnosis and Management of Diverticular Disease: Understanding Similarities and Differences. EMJ Gastroenterology 2018; : 40 doi: 10.33590/emjgastroenterol/10311869
|
| 107 |
Wanting Yang, Gaoyue Guo, Chao Sun. Therapeutic potential of rifaximin in liver diseases. Biomedicine & Pharmacotherapy 2024; 178: 117283 doi: 10.1016/j.biopha.2024.117283
|
| 108 |
Xi-Chen Zhao, Li Zhao, Xiao-Yun Sun, Zeng-Shan Xu, Bo Ju, Fan-Jun Meng, Hong-Guo Zhao. Excellent response of severe aplastic anemia to treatment of gut inflammation: A case report and review of the literature. World Journal of Clinical Cases 2020; 8(2): 425-435 doi: 10.12998/wjcc.v8.i2.425
|
| 109 |
Sima Vadaei, Payam Gonbari Milani, Roya Abedi Soleimani, Azar Abedi Soleimani. Gut Microbiota: a Perspective for Postpartum Depression. Gastrointestinal Nursing 2023; 21(4): 30 doi: 10.12968/gasn.2023.21.4.30
|
| 110 |
Antonio Tursi, Carmelo Scarpignato, Lisa L. Strate, Angel Lanas, Wolfgang Kruis, Adi Lahat, Silvio Danese. Colonic diverticular disease. Nature Reviews Disease Primers 2020; 6(1) doi: 10.1038/s41572-020-0153-5
|
| 111 |
Tilman Sauerbruch, Robert Schierwagen, Jonel Trebicka. Managing portal hypertension in patients with liver cirrhosis. F1000Research 2018; 7: 533 doi: 10.12688/f1000research.13943.1
|
| 112 |
Vincenzo Di Leo, Patrick J. Gleeson, Fabio Sallustio, Carine Bounaix, Jennifer Da Silva, Gesualdo Loreto, Sanae Ben Mkaddem, Renato C. Monteiro. Rifaximin as a Potential Treatment for IgA Nephropathy in a Humanized Mice Model. Journal of Personalized Medicine 2021; 11(4): 309 doi: 10.3390/jpm11040309
|
| 113 |
Vincenzo Di Leo, Francesca Annese, Federica Papadia, Iris Cara, Marica Giliberti, Fabio Sallustio, Loreto Gesualdo. The Landscape of IgA Nephropathy Treatment Strategy: A Pharmacological Overview. Future Pharmacology 2023; 3(2): 517 doi: 10.3390/futurepharmacol3020033
|
| 114 |
Moira B. Hilscher. A Helpful Bug in the System: Gut Microbes and Their Positive Impact on Portal Pressure Modulation. Cellular and Molecular Gastroenterology and Hepatology 2024; 18(6): 101399 doi: 10.1016/j.jcmgh.2024.101399
|
| 115 |
Carmelo Scarpignato, Giovanni Barbara, Angel Lanas, Lisa L. Strate. Management of colonic diverticular disease in the third millennium: Highlights from a symposium held during the United European Gastroenterology Week 2017. Therapeutic Advances in Gastroenterology 2018; 11 doi: 10.1177/1756284818771305
|
| 116 |
Jae Gon Lee, Chang Soo Eun, Su Vin Jo, A-reum Lee, Chan Hyuk Park, Dong Soo Han, Hiroyasu Nakano. The impact of gut microbiota manipulation with antibiotics on colon tumorigenesis in a murine model. PLOS ONE 2019; 14(12): e0226907 doi: 10.1371/journal.pone.0226907
|
| 117 |
Francesca Romana Ponziani, Barbara Funaro, Andrea Lupascu, Maria Elena Ainora, Matteo Garcovich, Gianluigi Caracciolo, Alessandro Quadarella, Antonio Nesci, Laura Riccardi, Antonio Gasbarrini, Maurizio Pompili, Maria Assunta Zocco. Minimal Hepatic Encephalopathy is Associated with Increased Cerebral Vascular Resistance. A Transcranial Doppler Ultrasound Study. Scientific Reports 2019; 9(1) doi: 10.1038/s41598-019-51867-6
|
| 118 |
Taylor Hori, Yaw B. Owusu, Dianqing Sun. Encyclopedia of Infection and Immunity. 2022; : 556 doi: 10.1016/B978-0-12-818731-9.00144-0
|
| 119 |
N. V. Orlova, D. V. Lukanin. Diverticular disease of colon. Unresolved issues. Medical alphabet 2019; 2(27): 26 doi: 10.33667/2078-5631-2019-2-27(402)-26-31
|